This company has been acquired
GreenLight Biosciences Holdings Past Earnings Performance
Past criteria checks 0/6
GreenLight Biosciences Holdings's earnings have been declining at an average annual rate of -41.7%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been growing at an average rate of 577.3% per year.
Key information
-41.7%
Earnings growth rate
93.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 577.3% |
| Return on equity | -717.2% |
| Net Margin | -1,521.0% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Revenue & Expenses Breakdown
How GreenLight Biosciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 10 | -157 | 35 | 0 |
| 31 Dec 22 | 7 | -167 | 36 | 0 |
| 30 Sep 22 | 4 | -163 | 34 | 0 |
| 30 Jun 22 | 3 | -154 | 31 | 0 |
| 31 Mar 22 | 2 | -129 | 26 | 0 |
| 31 Dec 21 | 2 | -112 | 20 | 0 |
| 30 Sep 21 | 1 | -86 | 17 | 0 |
| 30 Jun 21 | 2 | -89 | 15 | 0 |
| 31 Mar 21 | 2 | -75 | 13 | 0 |
| 31 Dec 20 | 2 | -53 | 11 | 0 |
| 31 Dec 19 | 3 | -37 | 9 | 0 |
Quality Earnings: GRNA is currently unprofitable.
Growing Profit Margin: GRNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GRNA is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.
Accelerating Growth: Unable to compare GRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-43.2%).
Return on Equity
High ROE: GRNA has a negative Return on Equity (-717.16%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/25 10:39 |
| End of Day Share Price | 2023/07/21 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GreenLight Biosciences Holdings is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Burleson | Canaccord Genuity |
| John Ezekiel Roberts | Credit Suisse |